Jefferies analyst Anthony Petrone views Antares Pharma's Q1 report as "solid" ahead of a "catalyst rich" second half of 2017. The better than expected results reflect continued strength in Sumatriptan device sales to Teva (TEVA) and a rebound in Otrexup, Petrone tells investors in a post-earnings research note. He believes four new products can win clearance in the second half of the year. Petrone sees the stock getting to $15 over time on successful launches from current pipeline products and keeps a Buy rating on Antares with a $6 price target. The stock in afternoon trading is down 4% to $2.67.